AstraZeneca Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

IgG antibody levels against the SARS-CoV-2 spike protein in mother –child dyads after COVID-19 vaccination
ConclusionsCOVID-19 mRNA vaccines induce high anti-SARS-CoV-2 S titers in pregnant women, which can inhibit the binding of ACE2 to protein S and are efficiently transferred to the fetus. However, there was a rapid decrease in antibody levels at 2 to 3 months post-partum, particularly in infants. (Source: Infection)
Source: Infection - October 28, 2023 Category: Infectious Diseases Source Type: research

Differences in CT presentation of covid 19 between vaccinated and unvaccinated patients
Conclusions: Prevention is the best way to deal with covid 19. Patients with three or more doses had less problems, mostly fatigue. Long covid in vaccinated patients was present but in mild forms. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Ivkovic, A., Milosavljevic, T., Svilarov, I., Ivkovic, S., Ivkovic, D. Tags: Imaging Source Type: research

Characteristics of severe asthma patients included in the French Palomb Cohort.
Conclusion: These are preliminary results of an observatory of patients followed with severe asthma in the French medical framework.Sponsors: Bordeaux University Foundation, AstraZeneca, Chiesi, GSK, Novartis, Sanofi. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Jestin-Guyon, N., Ouaalaya, E. H., Ozier, A., Nocent, C., Bernady, A., Nguyen, L., Berteaud, E., Dupuy-Grasset, M., Le Guillou, F., Melloni, B., Portel, L., PrudHomme, A., Didier, A., Molimard, M., Guilleminault, L., Raherison-Semjen, C. Tags: Epidemiology Source Type: research

Late Breaking Abstract - Patients with severe eosinophilic asthma achieved remission over 2 years with benralizumab: Integrated analysis of the >1000-patient, multinational, real-world XALOC-1 study
Conclusion: Clinical remission is a realistic, sustainable goal up to 2 years for pts with SEA receiving benralizumab, regardless of prior biologic experience.Funding: AstraZeneca (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Pelaia, G., Jackson, D. J., Nair, P., Emmanuel, B., Tran, T. N., Menzies-Gow, A., Watt, M., Kayaniyil, S., Boarino, S., Nuevo, J., Pardal, M., Shavit, A., Shih, V., Cohen, D., Loureiro, C., Padilla-Galo, A. Tags: Airway pharmacology and treatment Source Type: research

Late Breaking Abstract - Investigation of cKIT driven bone marrow toxicity and translation to human
In conclusion, identifying cKIT as an off-target, combining the PK/PD understanding of rat iTOX data and the MPS-based mathematical modelling of clinical haematotoxicity provided confidence to progress the compound into clinical development and informed the Ph1 study design. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Larsson, M., Gill, S., Pin, C., Pachl, F., Khan, K., Cartwright, J., Macdonald, R., Rose, J., Clayton, B., Leonard, E., Hornberg, J., Ollerstam, A., Larner, C. Tags: Mechanisms of lung injury and repair Source Type: research

Development of a high throughput primary human fibroblast-to-myofibroblast transition assay
In conclusion a stable high throughput FMT assay in primary human lung fibroblasts has been optimised to be run in 384 well format. (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Bäck, E., Ding, M., Jirholt, J., Reijer, J., Tangefjord, S. Tags: Airway cell biology and immunopathology Source Type: research

Benralizumab increases time to recurrent exacerbations in COPD patients on triple therapy with frequent exacerbations and an eosinophilic phenotype
Conclusion: This analysis suggests that benralizumab 100 mg may reduce the risk of, or prolong time free from, a recurrent ECOPD in this subgroup and supports continued investigation of benralizumab in COPD in the ongoing phase 3 RESOLUTE (NCT04053634) study.Funding: This study was funded by AstraZeneca (Södertälje, Sweden). (Source: European Respiratory Journal)
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Singh, D., Crine, G. J., Agusti, A., Bafadhel, M., Söderström, J., Luporini Saraiva, G., Fan, Y., Jison, M., Martin, U. J., Psallidas, I. Tags: Airway pharmacology and treatment Source Type: research

High-content imaging assays to monitor the effects of cigarette smoke on mitochondrial health
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction resulting from small airway disease, disappearance of bronchioles and emphysema with the destruction of alveolar walls. In some individuals, dysfunctional mitochondria, unable to indefinitely maintain homeostasis and respond to chronic stress, precipitate changes in epithelial structure and biology that dictate the onset of COPD and disease course.At AstraZeneca, with the aim of disease modification and ultimately cure, we are committed to detecting COPD early and treating the underlying disease drivers. With the work presented...
Source: European Respiratory Journal - October 27, 2023 Category: Respiratory Medicine Authors: Karlsson, M., Wennberg, T., Skogberg, G., Jirholt, J. Tags: Mechanisms of lung injury and repair Source Type: research

Vaccine-induced SARS-CoV-2 antibody response: the comparability of S1-specific binding assays depends on epitope and isotype discrimination
ConclusionAll three binding assays allow monitoring of the antibody response in COVID-19-vaccinated individuals. However, the assay-specific differences hinder the definition of a common protective threshold in BAU/ml. Our results highlight the need for the thoughtful use of conversion factors and consideration of method-specific differences. To improve the management of future pandemics and harmonize total antibody assays, we should strive for reference material with a well-characterized Ig isotype composition. (Source: Frontiers in Immunology)
Source: Frontiers in Immunology - October 26, 2023 Category: Allergy & Immunology Source Type: research

Molecules, Vol. 28, Pages 7220: An Ultrafast UPLC & ndash;MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib
Molecules, Vol. 28, Pages 7220: An Ultrafast UPLC–MS/MS Method for Characterizing the In Vitro Metabolic Stability of Acalabrutinib Molecules doi: 10.3390/molecules28207220 Authors: Mohamed W. Attwa Ahmed H. Bakheit Ali S. Abdelhameed Adnan A. Kadi Acalabrutinib, commercially known as Calquence&reg;, is a pharmacological molecule that has robust inhibitory activity against Bruton tyrosine kinase. The medicine in question was carefully developed by the esteemed pharmaceutical company AstraZeneca. The FDA granted authorization on 21 November 2019 for the utilization of acalabrutinib (ACB) in t...
Source: Molecules - October 23, 2023 Category: Chemistry Authors: Mohamed W. Attwa Ahmed H. Bakheit Ali S. Abdelhameed Adnan A. Kadi Tags: Article Source Type: research

Corrigendum to "Comparison of Astra Zeneca and sinopharm vaccines as boosters in protection against COVID-19 infection" [Biologicals 82 (2023) 101668]
Biologicals. 2023 Oct 20;84:101719. doi: 10.1016/j.biologicals.2023.101719. Online ahead of print.NO ABSTRACTPMID:37866229 | DOI:10.1016/j.biologicals.2023.101719 (Source: Biologicals : Journal of the International Association of Biological Standardization)
Source: Biologicals : Journal of the International Association of Biological Standardization - October 22, 2023 Category: Biotechnology Authors: Arash Letafati Nooshin Eyvazzadeh Amirhossein Gharehkhani Ayeh Khorshidian Siavash Chalabiani Elnaz Khodadoust Soufiani Niloofar Khakpoor Benyamin Shamsodini Taranom Beheshti Raha Taheri Bavili Olyaei Anahita Soleimani Fatemeh Melyani Ghazal Mashhadi Hoss Source Type: research